IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$3.98
-0.23 (-5.46%)
▼
5d:
-10.96%
30d:
+9.64%
90d:
+9.04%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
21d
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called IRWD this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IRWD is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IRWD is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.79
41.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $3.98, which is considered fair relative to its 30-day fair value range of $3.50 to $4.37. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.8) compared to its historical average (3.9). Remarkably, the market is currently pricing in an annual earnings decline of 11.1% over the next few years. This pessimistic expectation contrasts with the company's recent 1046.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is currently testing key support at $3.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.10 (+53.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is currently testing key support at $3.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.10 (+53.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.50 -
$4.37
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.5%)
- BULLISH: Trading 53.3% below Wall St target ($6.10)
- WARNING: Recommendation downgraded due to -11.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.50 -
$4.37
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.97
Resistance Level
$4.88
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.76
Wall Street Target
$6.10
(+53.3%)
Revenue Growth (YoY)
158.9%
Earnings Growth (YoY)
1046.8%
Profit Margin
28.3%
Valuation Discount vs History
-11.1% cheaper
PE vs Historical
2.8 vs 3.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.1%
(market-implied from PE analysis)
1-Year Target
$3.58
(-10%)
2-Year Target
$3.22
(-19%)
3-Year Target
$2.90
(-27%)
3-Yr Target (if PE normalizes)
(PE: 3→4)
$4.09
(+3%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 32.1%)
$72.31
(+1717%)
Base:
(SPY PE: 2.8, Growth: 32.1%)
$9.18
(+131%)
Bear:
(PE: 2.3, Growth: 32.1%)
$7.80
(+96%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (7x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 7.21 | Current EPS (TTM): $0.62
Bull Case
$9.83
(+147%)
Analyst growth 100.0%, PE expands to 7.9
Base Case
$8.94
(+125%)
Market implied 100.0%, PE stable at 7.2
Bear Case
$3.04
(-24%)
Severe decline -20.0%, PE contracts to 6.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.8 to 3.9
Stabilization Target:
$5.62
(+41.1%)
PE Expansion Potential:
+41.1%
Share & Embed Analysis
Last updated: July 15, 2026 3:55 AM ET
Data refreshes hourly during market hours. Next update: 4:55 AM
Data refreshes hourly during market hours. Next update: 4:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander J Denner
SELL
6730800 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
